Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231010 · ClinicalTrials.gov registry record
Molecular Genetics of Retinal Degenerations
A clinical trial of Retinitis Pigmentosa and Retinal Degeneration, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 3,549
- Enrollment target
- 6
- Study locations
NCT00231010: Completed study of Retinitis Pigmentosa and Retinal Degeneration, sponsored by National Eye Institute (NEI).
NCT00231010 is a study of Retinitis Pigmentosa and Retinal Degeneration that has completed, run by National Eye Institute (NEI). The registered enrollment target is 3,549 participants, above the 165-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (2051% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00231010, a study of Retinitis Pigmentosa and Retinal Degeneration, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 3,549 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multinational study will investigate the inheritance of genetic retinal degeneration in families of different nationalities and ethnic backgrounds in order to identify the genes that, when altered, cause retinal degeneration. The retina is a light-sensitive membrane lining the back part of the eye. It relays vision signals to the brain, which the brain interprets into sight. When the retina degenerates, vision is altered and possibly lost. The findings of this study should help improve diagnosis and methods of treatment for these disorders. Participating institutions include: the National Institutes for Health in Bethesda, Maryland; the University of Miami in Florida; the Casey Eye Institute in Portland, Oregon; the Byrd Health Sciences Center in Morgantown, West Virginia; the University of Texas Southwestern Medical School in Dallas, Texas; the University of Tennessee Health Sciences Center in Memphis; the Prasad Eye Institute in Hyderabad, India; National Center of Excellence in Molecular Biology in Lahore, Pakistan; and the Jules Gonin Hospital in Lausanne, Switzerland. Patients with retinitis pigmentosa and closely related diseases such as Usher syndrome, snowflake vitreoretinal dystrophy and Bietti crystalline dystrophy may be eligible for this study. Participants undergo the following tests and procedures: * Medical and surgical history, including family history of vision problems. * Examination to clarify the type of retinal degeneration. * Eye examination, including tests of color vision, field of vision and ability to see in the dark * Electroretinogram to test the function of visual cells. For this test, the patient sits in a dark room for 30 minutes with his or her eyes patched. Then, a small electrode (silver disk) is taped to the forehead and the eye patches are removed. The surface the eyes is numbed with eye drops, and contact lenses are placed on the eyes. The patient looks inside a large dark globe that emits a series of light flashes. Then a
Conditions Studied
Study Locations (6)
Other
- Sun Yat-Sen University - Guangzhou
- Aravind Eye Hospital - Maduri
- University of Punjab - Lahore
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Massachusetts
- Harvard Medical School - Boston
Ohio
- Cleveland Clinic Foundation Childrens Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,549 participants |
| Start Date | 2005-09-26 |
| Est. Completion | 2016-06-23 |
What the finished NCT00231010 record still lists
NCT00231010 is an observational study that tracks outcomes without assigning an intervention. Its 3,549 participants enrollment target places it among the larger protocols in the corpus, above the 165-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (2051% higher).
The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.
NCT00231010 lists 6 locations in 4 states (Other, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00231010 about?
NCT00231010 is a clinical study titled "Molecular Genetics of Retinal Degenerations". This multinational study will investigate the inheritance of genetic retinal degeneration in families of different nationalities and ethnic backgrounds in order to identify the genes that, when altered, cause retinal degeneration. The retina is a light-sensitive membrane lining the back part of the ...
What is the current status of trial NCT00231010?
This trial is currently completed. The enrollment target is 3,549 participants. The study started on 2005-09-26. Estimated completion is 2016-06-23.
What conditions does trial NCT00231010 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Degeneration.
Who is sponsoring clinical trial NCT00231010?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00231010 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00231010's enrollment target sits among peer trials
3,549 1st of 37 higher than 37 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Retinal Imaging in Patients With Inherited Retinal Degenerations
RECRUITING
-
Cell Collection to Study Eye Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06429787 · 3,574 participants
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- NCT03199651 · 3,584 participants · NA
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI